Orion Corporation Secures US FDA Approval for Tessie to Treat Noise Aversion & Separation Anxiety in Dogs

Quick Takeaways

Orion announced that the US FDA approved Tessie (tasipimidine oral solution) on May 6, 2026, for the treatment of noise aversion and separation anxiety in dogs

Tasipimidine is Orion’s proprietary molecule and a new active substance for veterinary use in the US. The therapy acts on the central nervous system by blocking the startle reflex to counteract arousal associated with anxiety-related conditions in dogs

Zoetis holds exclusive rights to market and commercialize Tessie in the US, with launch anticipated by mid-2027. The product will expand Zoetis’ behavioral medicine portfolio alongside Sileo and Bonqat

Why It Matters?

A new proprietary CNS asset from Orion, exclusively commercialized by Zoetis in the US, that taps into fast‑growing demand for medical management of canine anxiety and should expand the addressable market beyond situational noise phobia toward more chronic, everyday separation‑related distress ahead of a planned mid‑2027 launch.

Source: Globenewswire

Tanya B

Tanya is a skilled editor at AnimalHealthX, where she plays a key role in shaping high-quality content across animal healthcare. With a keen eye for detail and a strong grasp of industry trends, she ensures every article, interview, and report is accurate, engaging, and impactful. Passionate about storytelling and driven by curiosity, Tanya brings clarity and consistency to complex topics, helping AnimalHealthX deliver trusted insights to its global audience.